KIT mutation-NTRK fusion oncogenic driver switch: A novel mechanism of acquired imatinib resistance in GIST

Researchers identified a novel mechanism of acquired imatinib resistance in gastrointestinal stromal tumors. A specific case study revealed an oncogenic driver switch from a KIT mutation to an EML4::NTRK3 fusion. This fusion confers resistance to imatinib while sensitizing tumor cells to NTRK inhibitors. Consequently, testing resistant tumors for NTRK alterations is crucial for offering patients expanded therapeutic options.